Med. praxi. 2017;14(4):207-211 | DOI: 10.36290/med.2017.040

Primary detection of arterial hypertension in a patient with a risk history

MUDr. Kateřina Študentová
Všeobecná praktická lékařka, Plzeň

The case report describes detection of essential arterial hypertension in a young patient. This patient’s cardiovascular risk is lowaccording to the SCORE chart. However, given his alarming family history and unhealthy lifestyle, he needs to be considered, inthe long-term perspective, a high-risk patient. The treatment of such a patient must be managed properly since the beginning. Itis necessary to choose an antihypertensive drug providing maximum cardiovascular protection at a dose that will control bloodpressure sufficiently. It is important to motivate the patient to change his lifestyle, particularly in terms of rational eating, sufficientregular physical activity, and appropriate rest.

Keywords: arterial hypertension, perindopril arginine, cardiovascular risk

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Študentová K. Primary detection of arterial hypertension in a patient with a risk history. Med. praxi. 2017;14(4):207-211. doi: 10.36290/med.2017.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Škodová Z, Lánská V, et al. Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nation wide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. Journal of Human Hypertension 2004: 18; 571-579. Go to original source... Go to PubMed...
    2. Karen I, Filipovský J. Arteriální hypertenze. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Novelizace 2014. CDP-PL.
    3. Býma S, Hradec J. Prevence kardiovaskulárních onemocnění. DDP-PL, 2013.
    4. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal 2012; 33: 1635-1701.
    5. Špinar J, Vítkovec J. Perindoprilum. Remedia 2005; 15: 121-135.
    6. DiNicolantonio JJ, Lavie CJ, O'Keefe JH. Not All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and Perindopril Postgraduate Medicine 2013; 125(4): 154-168. Go to original source... Go to PubMed...
    7. Ferrari, R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review Expert Rev. Cardiovasc. Ther. 2013; 11(6): 705-717. Go to original source... Go to PubMed...
    8. Fox KM, et al. Efficacy of perindopril in reduction of cardiovascular events among patiens with stable coronary artery disease: randomised, double blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-788. Go to original source... Go to PubMed...
    9. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimenamong 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041. Go to original source... Go to PubMed...
    10. Van Vark L, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of RAAS inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088-2097. Go to original source... Go to PubMed...
    11. Savarese G, Costanzo P, Cleland JG, et al. A metaanalysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131-142. Go to original source... Go to PubMed...
    12. Cheng J, Zhang W, Zhang X, et al. Effectof angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovasculardeaths, and cardiovascularevents in patiens with diabetes mellitus. JAMA Intern Med 2014; 174: 773-785. Go to original source... Go to PubMed...
    13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153. Go to original source...
    14. Tsoukas G, Anand S, Yang K, Dose-Dependent Antihypertensive Efficacy and Tolerability of Perindopril in a Large Observational, 12-Week, General Practice-Based Study, Am J CardiovascDrugs 2011; 11(1): 45-55. Go to original source... Go to PubMed...
    15. Filipovský J, Widimský J jr., Špinar J. Doporučení ESH/ESC pro diagnostiku a léčbu hypertenze - verze 2013. Zkrácený překlad. Česká společnost pro hypertenzi.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.